← FDA DRUG APPROVALS

FDA ANDA · ANDA202637

LANSOPRAZOLE

Sponsor: SUN PHARM

APPLICATION
ANDA202637
TYPE
ANDA
ORIGINAL APPROVAL
2013-09-13
LATEST ACTION
2022-09-02
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Discontinued

Products

LANSOPRAZOLEDiscontinued
LANSOPRAZOLE 15MG · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2022-09-02Labeling · Supplement 18 · standardAP
2020-10-20Labeling · Supplement 6 · standardAP
2020-10-20Labeling · Supplement 15 · standardAP
2020-10-20Labeling · Supplement 9 · standardAP
2020-10-20Labeling · Supplement 8 · standardAP
2015-03-17Labeling · Supplement 5 · standardAP
2013-09-13UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →